← Eichor
Study identifier: NCT07080905 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B

Condition: Hemophilia B  ·  Sponsor: CSL Behring

PhasePhase 3
Planned participants20
Who can joinMale, 138 Months to 206 Months
Healthy volunteersNo

About this study

This is a phase 3, prospective, open-label, single-arm, single-dose, multicenter study investigating the efficacy, safety, and tolerability of CSL222 (AAV5-hFIXco-Padua) in adolescent male participants with severe or moderately severe hemophilia B.

This description comes directly from the study's public registry record.

Talk to the study team

Trial Registration Coordinator  ·  1-610-878-4697  ·  clinicaltrials@cslbehring.com

Always discuss trial participation with your own doctor first.

Locations (12)

Center for Inherited Blood DisordersOrange, California, United StatesRecruiting
University of FloridaGainesville, Florida, United StatesRecruiting
Arthur M. Blank Hospital - Children's Healthcare of AtlantaAtlanta, Georgia, United StatesRecruiting
University of Michigan Medical CenterAnn Arbor, Michigan, United StatesRecruiting
St. Jude Children's Research HospitalMemphis, Tennessee, United StatesRecruiting
Medical University ViennaVienna, AustriaRecruiting
UZ Leuven - Centrum voor Moleculaire en Vasculaire BiologieLeuven, BelgiumRecruiting
Chaim Sheba Medical CenterRamat Gan, IsraelRecruiting
Hospital Sant Joan de DéuBarcelona, SpainRecruiting
La Paz University HospitalMadrid, SpainRecruiting
St Thomas HospitalLondon, United KingdomRecruiting
John Radcliffe Hospital - Oxford University Hospitals NHSOxford, United KingdomRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07080905